
Zura Bio Limited – NASDAQ:ZURA
Zura Bio Limited stock price today
Zura Bio Limited stock price monthly change
Zura Bio Limited stock price quarterly change
Zura Bio Limited key metrics
Market Cap | 144.29M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.36 |
Revenue | N/A |
EBITDA | -64.22M |
Income | -51.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZura Bio Limited stock price history
Zura Bio Limited stock forecast
Zura Bio Limited financial statements
$10
Potential upside: 464.33%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -34.02M | |
---|---|---|---|
Sep 2023 | 0 | -8.27M | |
Dec 2023 | 0 | -8.47M | |
Mar 2024 | 0 | -730K |
2023-11-13 | -0.25 | -0.18 |
---|---|---|
2024-03-26 | -0.25 | -0.19 |
2024-05-09 | -0.23 | -0.02 |
Jun 2023 | 113332000 | 22.00M | 19.42% |
---|---|---|---|
Sep 2023 | 104592000 | 18.96M | 18.13% |
Dec 2023 | 100843000 | 21.29M | 21.11% |
Mar 2024 | 90483000 | 16.27M | 17.98% |
Jun 2023 | -5.17M | -5.75M | 79.76M |
---|---|---|---|
Sep 2023 | -2.57M | -2.25M | -4.12M |
Dec 2023 | -4.05M | 0 | 0 |
Mar 2024 | -4.98M | -5.00M | 0 |
Zura Bio Limited alternative data
Mar 2024 | 14 |
---|---|
Apr 2024 | 14 |
May 2024 | 14 |
Jun 2024 | 14 |
Jul 2024 | 14 |
Zura Bio Limited other data
Period | Buy | Sel |
---|---|---|
Apr 2024 | 1357827 | 0 |
May 2024 | 80000 | 0 |
Sep 2024 | 0 | 3851728 |
Nov 2024 | 0 | 1001633 |
-
What's the price of Zura Bio Limited stock today?
One share of Zura Bio Limited stock can currently be purchased for approximately $1.77.
-
When is Zura Bio Limited's next earnings date?
Unfortunately, Zura Bio Limited's (ZURA) next earnings date is currently unknown.
-
Does Zura Bio Limited pay dividends?
No, Zura Bio Limited does not pay dividends.
-
How much money does Zura Bio Limited make?
Zura Bio Limited has a market capitalization of 144.29M. Zura Bio Limited made a loss 60.36M US dollars in net income (profit) last year or -$0.02 on an earnings per share basis.
-
What is Zura Bio Limited's stock symbol?
Zura Bio Limited is traded on the NASDAQ under the ticker symbol "ZURA".
-
What is Zura Bio Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Zura Bio Limited?
Shares of Zura Bio Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Zura Bio Limited have?
As Jul 2024, Zura Bio Limited employs 14 workers.
-
When Zura Bio Limited went public?
Zura Bio Limited is publicly traded company for more then 2 years since IPO on 21 Mar 2023.
-
What is Zura Bio Limited's official website?
The official website for Zura Bio Limited is zurabio.com.
-
Where are Zura Bio Limited's headquarters?
Zura Bio Limited is headquartered at 4225 Executive Square, San Diego, CA.
-
How can i contact Zura Bio Limited?
Zura Bio Limited's mailing address is 4225 Executive Square, San Diego, CA and company can be reached via phone at 858 247 0520.
-
What is Zura Bio Limited stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Zura Bio Limited in the last 12 months, the avarage price target is $10. The average price target represents a 464.33% change from the last price of $1.77.
Zura Bio Limited company profile:

Zura Bio Limited
zurabio.comNASDAQ
14
Biotechnology
Healthcare
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
San Diego, CA 92037
CIK: 0001855644
ISIN: KYG9TY5A1016
: